General Information |
| Summary |
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months. |
| Description |
Not Provided |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2017-07-05 |
| End date (estimated) |
2018-02-15 |
| Clinical feature |
| Label |
type 1 diabetes mellitus |
| Link |
http://purl.obolibrary.org/obo/DOID_9744 |
| Description |
A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT03162926 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03162926 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/study/NCT03162926 |
| Regulatory body approval |
| Name |
Food and Drug Administration (FDA) |
| Country |
|
|
| Public contact |
| Email |
info@viacyte.com |
| Public email |
info@viacyte.com |
| Country |
|
|
| Sponsors |
ViaCyte
|
Cells |
| Source pluripotent stem cell lines |
|
| Which differentiated cell type is used |
| Label |
progenitor cell of endocrine pancreas |
| Link |
http://purl.obolibrary.org/obo/CL_0002351 |
| Description |
A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1. |
|
Recruitment |
| Recruitment Status |
Completed |
| Estimated number of participants |
3 |
